TL;DR
Dallas-Fort Worth medical device companies need products liability towers sized to device class, IDE clinical trial coverage during studies, and additional-insured terms that satisfy hospital and GPO purchase contracts. Ophthalmic, implantable, and connected devices concentrate the exposure, and the most common gap is a blanket additional-insured endorsement that quietly excludes products and completed operations.
Dallas & Fort Worth medical device
The Dallas-Fort Worth metroplex carries a real and specialized medical device presence, with Fort Worth in particular anchoring eye-care, ophthalmic, and dermatology device and product operations alongside a broad base of device manufacturers and distributors. That mix sits inside one of the largest hospital and health-system markets in the country, which means DFW device companies routinely sell into major purchasing organizations and health systems that dictate insurance terms through their supplier contracts.
Insuring a device company here is less about a single general liability policy and more about assembling a coverage architecture that tracks the product from design and clinical study through commercial distribution. The right program aligns the products liability tower to the device's regulatory class, carries the correct clinical trial and recall triggers, and drafts additional-insured language precisely enough to clear GPO and hospital contract requirements without leaving completed operations exposed.
Last updated 2026-07-14
Cluster shape
Fort Worth is a recognized hub for ophthalmic and dermatology device and product companies, and the wider metroplex adds contract manufacturers, component suppliers, and national distributors that move product into hospitals and surgical centers. This concentration in eye-care and interventional products matters for underwriting, because implantable and ophthalmic devices sit at the higher-severity end of the products liability spectrum.
Because DFW is one of the densest hospital and health-system markets in the region, local device companies sell through group purchasing organizations and directly to health systems far more than a typical manufacturer would. Those channels bring standardized contract language that pushes specific insurance requirements onto the supplier, and a program that ignores those requirements can stall a purchase order.
Texas is a business-dense state with deep surplus-lines availability, which gives DFW device companies access to A-rated specialty markets that can build tailored towers for higher-hazard product lines. That access is an advantage, but only when the placement is structured to the device class and the contractual obligations the company has actually signed.
Coverage architecture
The foundation is products liability sized to the device class. Class I products may sit comfortably on modest primary limits, while Class II and especially Class III implantable, interventional, and ophthalmic devices typically carry higher towers assembled across primary and excess layers, with market-typical program limits often ranging from roughly $5M to $25M or more depending on hazard, revenue, and contractual demands. Companies running IDE clinical studies also need clinical trial coverage in force during the investigation, since study-phase bodily injury exposure is distinct from commercial products liability.
Hospital purchase contracts and GPO supplier agreements, including those administered through organizations such as Vizient, Premier, and HealthTrust, frequently require the device company to name the customer as an additional insured for both products AND completed operations, on a primary and non-contributory basis, at specified limits. Meeting those terms is a drafting exercise as much as a limits exercise, and getting the endorsement language right is what allows the supplier agreement to close.
Two further triggers round out a complete program. Product recall should be carried as a separate first-party coverage, since recall response and withdrawal costs are a distinct exposure from third-party bodily injury. For software-driven and connected devices, cyber and technology E&O increasingly become a primary product-liability vehicle, because software as a medical device (SaMD) failures manifest as coding or performance defects rather than traditional manufacturing flaws.
Regulatory + market context
The most common and most damaging gap we see is a blanket additional-insured endorsement that appears to satisfy a customer requirement but actually excludes products and completed operations, which is precisely the exposure a device supplier needs covered. Because GPO and hospital agreements demand additional-insured status for products and completed operations specifically, a generic blanket form can leave the company technically noncompliant with a contract it has already signed.
Device class also drives the regulatory backdrop that shapes coverage. Class III implantables and interventional products face the most stringent oversight and the highest severity potential, ophthalmic products carry their own heightened profile, and connected or software-driven devices introduce SaMD and cybersecurity considerations that a conventional products policy was never designed to answer. Aligning the insurance program to the actual class and technology of each product line is what keeps the coverage matched to the real exposure.
Frequently asked
DFW combines a specialized device base, notably Fort Worth's ophthalmic and dermatology cluster, with one of the largest hospital and health-system markets in the region. That means local device companies sell heavily through GPOs and health systems whose contracts impose specific insurance requirements, so a DFW program has to be built to clear those supplier agreements while sizing the products tower to the device class.
Class drives severity. Class I devices often sit on modest primary limits, while Class II and Class III implantable, interventional, and ophthalmic devices typically require higher towers assembled across primary and excess layers, with market-typical programs frequently ranging from roughly $5M to $25M or more. The final structure depends on the specific device hazard, revenue, and the limits customers contractually demand.
Group purchasing organization and hospital supplier agreements, including those run through organizations such as Vizient, Premier, and HealthTrust, commonly require the customer to be named as an additional insured for both products AND completed operations, on a primary and non-contributory basis, at specified limits. The endorsement language has to be drafted to match those terms, because a blanket additional-insured form that excludes products or completed operations can leave the supplier out of compliance.
For software as a medical device (SaMD) and connected products, cyber and technology E&O often become the primary product-liability vehicle, because failures show up as software defects or performance errors rather than traditional manufacturing flaws. A complete program pairs the products liability tower with cyber and technology E&O so that both physical and software failure modes are addressed.
Free coverage review
Programs placed through A-rated specialty markets. Send your contract, insurance schedule, or current COI - a specialist returns a clause-by-clause read by end of business day.